# Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/ramucirumab-plus-pembrolizumab-in-patients-with-previously-treated-advanced-non/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Roy S. Herbst,Hendrik‐Tobias Arkenau,Rafael Santana-Dávila,Emiliano Calvo,Luis Paz‐Ares,Philippe A. Cassier,Johanna C. Bendell,Nicolas Penel,Matthew Krebs,Juan Martín-Liberal,Nicolás Isambert,A. Segado Soriano,Martin Wermke,Jennifer L. Cultrera,Ling Gao,Ryan C. Widau,Gu Mi,Jin Jin,David Ferry,Charles S. Fuchs,Daniel P. Petrylak,Ian Chau |
| Citations | 275 |
| DOI | 10.1016/s1470-2045(19)30458-9 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://research.manchester.ac.uk/en/publications/89db125f-08de-4bf6-a673-5d0e898679aa |
| OpenAlex ID | https://openalex.org/W2958083922 |
| PMID | 31301962 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Martin Wermke](https://scholariq.org/researchers/martin-wermke/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.